The investigators recently identified promiscuous HLA-DR-derived epitopes from the human telomerase reverse transcriptase (TERT) called universal cancer peptides (UCP), to study tumor-specific CD4+ T cell responses.

The investigators found high frequency of naturally occuring UCP-specific TH1 cells in long term survival of metastatic colorectal cancer (CRC) previously treated by 5 fluoro-uracil -oxaliplatin (Folfox) +/- bevacizumab regiment (Godet et al. OncoImmunology 2012 and unpublished data).

Epitopes-CRC02 is a French prospective multicenter study which will evaluate the post chemotherapy and post surgery modulation of host tumor-specific CD4 TH1 cell responses in metastatic colorectal cancer patients and their correlation with progression-free survival.

Inclusion Criteria:

• Performance status ECOG-WHO 0, 1 or 2
• Metastatic colorectal cancer Histologically proved
• signed written informed consent

Exclusion Criteria:

• previous treatment (chemotherapy, targeted therapy, surgery) for metastatic disease
• history of autoimmune disease
• patients under immunotherapy systemic treatment or immunosuppressive drugs or stopped for less than 6 months to the enrollment in this study.
• corticoids ≥ 1mg/kg
• acute or chronic infectious disease during treatment or stopped for less than six months
• other malignancy within the last 5 years, except for adequately treated carcinoma in situ of the cervix or squamous carcinoma of the skin, or adequately controlled limited basal cell skin cancer.
• pregnancy, breast-feeding or absence of adequate contraception for fertile patients
• patient with any medical or psychiatric condition or disease which would make the patient inappropriate for entry into this study.
• patient under guardianship, curator or under the protection of justice.